CompaniesGoldfinch Bio

Goldfinch Bio

defunct
About

Defunct Company

Areas of Focus

Categories

Bankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (5)
View all

Total Trials

5

As Lead Sponsor

5

As Collaborator

0

Total Enrollment

256

By Phase

PHASE2: 2PHASE1: 2

By Status

TERMINATED: 3COMPLETED: 2
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2018
2019
2020
2021
2022
2023
Today
NCT04387448
NCT04950114
Hover over trial bars to see details

Recent Trials

NCT04950114Lead Sponsor
An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases
PHASE2Terminated
31 participants
Started: Jul 27, 2021 · Completed: Nov 2, 2022
NCT04880291Lead Sponsor
First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes
PHASE1Completed
39 participants
Started: May 5, 2021 · Completed: Feb 8, 2022
NCT04387448Lead Sponsor
A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease
PHASE2Terminated
96 participants
Started: Jul 28, 2020 · Completed: Nov 1, 2022
NCT04235621Lead Sponsor
A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)
N/ATerminated
20 participants
Started: Dec 20, 2019 · Completed: May 27, 2020
NCT03970122Lead Sponsor
FIH Ph 1 Study of TRPC5 Channel Inhibitor GFB-887 in Healthy Subjects
PHASE1Completed
70 participants
Started: May 29, 2019 · Completed: Apr 4, 2020
Funding History (2)
D
Jul 14, 2020
Filing
D
Jan 23, 2017
Filing